Home | Contact NUI  


29 May 2023  

Dr Rachel D Moloney

Dr Rachel D Moloney

Dr Rachel D Moloney

Dr Rachel D Moloney is a Lecturer in the School of Pharmacy and Dept. of Pharmacology & Therapeutics, University College Cork. She received a B.Sc. (Hons) in Biochemistry from UCC in 2009 after which she received an M.Sc. in Neuropharmacology from National University of Ireland, Galway (NUIG).

Dr. Moloney completed her Ph.D. in the Dept of Psychiatry and Dept. Anatomy & Neuroscience, UCC in 2014. She then worked as a lab manager at APC Microbiome Ireland before pursuing post-doctoral fellowships at the University of Oklahoma Health Sciences Center, Oklahoma City, USA and the University of Cincinnati, Ohio, USA. Dr Moloney holds a NARSAD Young Investigator Award (2019-2021) from the Brain and Behavior Research foundation (USA). Dr Moloney's current research is focused on understanding the role of traumatic stress on brain circuitry and its impact on fear, social and pain behaviours, particularly in the context of PTSD, anxiety and depression. Additionally, Dr Moloney is affiliated with APC Microbiome Ireland where her research is aimed at understanding the role of the gut microbiome in trauma. Her lab utilizes cutting edge tools such as DREADDs, translationally relevant models and pharmacological manipulations to advance our knowledge of traumatic stress with the hope of aiding future drug discovery efforts.

Project supported by the NUI Grant Scheme:

Targeting Therapeutics for CNS Disorders 2020 is a one-day international symposium organized by early career faculty at the School of Pharmacy, University College Cork, Ireland.
The symposium itself is divided into 4 main sections;

  1. Pharmacology


  1. Clinical Pharmacy Practice

    Career Development

The theme of the symposium is to promote interdisciplinary research and tackle the challenges in treating neurological and neuropsychiatric conditions, for which there is an unmet medical need. We hope that by bringing together a range of experts in each of these areas and providing the platform to discuss and find commonality, that we can drive the development of cross-disciplinary research and to ultimately impact the quality of care we can provide our patients.

This bench to bedside approach is a key element of our symposium and our program is designed to encompass presentations from basic fundamental research to novel innovative drug delivery strategies to hearing first-hand the experience of living everyday life with a neurodegenerative disorder from a patient themselves. We hope delegates will find the day not only informative, from a scientific perspective but also motivational to pursue innovative research methods and most importantly, inspirational to continue to work toward patient-focused research.

Equality, diversity and inclusion are paramount to this symposium, and so the organizers have incorporated this into all levels of planning thus far. As an Athena Swan Bronze Award recipient, we (School of Pharmacy, UCC) are committed to ensuring this symposium is in line with our School’s mission and is an equitable, diverse and inclusive event.